Vivolution pushes forward PRF (platelet-rich fibrin) system with E7m
This article was originally published in Clinica
Executive Summary
Danish automated surgical sealant system developer Vivolution is to ramp up European sales of its Vivostat platelet-rich fibrin (PRF) technology, having secured Euro7m ($9.1m) in its third round of financing. The proceeds will also be used to initiate US clinical studies of the system for FDA approval. The round was led by French VC fund Seventure and Danish private equity firm Vecata. The Vivostat system, which is available widely as a device for the on-site preparation of autologous tissue sealant, has been developed to prepare platelet-rich fibrin for treating chronic wounds.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.